B. Riley Forecasts Cytokinetics’ Q1 Earnings (NASDAQ:CYTK)

Cytokinetics, Incorporated (NASDAQ:CYTK) – Equities research analysts at B. Riley issued their Q1 2026 EPS estimates for shares of Cytokinetics in a research report issued to clients and investors on Monday, November 10th. B. Riley analyst M. Mamtani expects that the biopharmaceutical company will post earnings of ($1.62) per share for the quarter. B. Riley has a “Buy” rating and a $90.00 price target on the stock. The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ Q2 2026 earnings at ($1.62) EPS, Q3 2026 earnings at ($1.67) EPS and Q4 2026 earnings at ($1.56) EPS.

Several other brokerages also recently weighed in on CYTK. Needham & Company LLC reiterated a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a report on Tuesday, September 2nd. Raymond James Financial assumed coverage on Cytokinetics in a research report on Wednesday, July 30th. They issued a “market perform” rating for the company. Bank of America upped their target price on Cytokinetics from $52.00 to $56.00 and gave the company a “neutral” rating in a research note on Thursday, October 2nd. Royal Bank Of Canada increased their target price on Cytokinetics from $82.00 to $87.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cytokinetics in a report on Wednesday, October 8th. Thirteen analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $77.86.

Cytokinetics Stock Performance

Shares of CYTK opened at $66.50 on Tuesday. Cytokinetics has a 1 year low of $29.31 and a 1 year high of $66.72. The company’s 50 day simple moving average is $56.14 and its 200 day simple moving average is $42.47. The company has a market capitalization of $8.13 billion, a price-to-earnings ratio of -13.04 and a beta of 0.58.

Cytokinetics (NASDAQ:CYTK) last released its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.59) by $0.05. The firm had revenue of $1.94 million for the quarter, compared to analyst estimates of $6.05 million. Cytokinetics’s revenue for the quarter was up 318.1% on a year-over-year basis. During the same period in the prior year, the business earned ($1.36) earnings per share.

Institutional Investors Weigh In On Cytokinetics

Several large investors have recently made changes to their positions in the business. Aberdeen Group plc increased its holdings in Cytokinetics by 53.2% in the 2nd quarter. Aberdeen Group plc now owns 922,929 shares of the biopharmaceutical company’s stock valued at $30,494,000 after purchasing an additional 320,508 shares in the last quarter. Zweig DiMenna Associates LLC purchased a new stake in shares of Cytokinetics in the second quarter worth about $1,176,000. Mirador Capital Partners LP grew its stake in shares of Cytokinetics by 45.6% in the second quarter. Mirador Capital Partners LP now owns 144,347 shares of the biopharmaceutical company’s stock valued at $4,769,000 after buying an additional 45,222 shares in the last quarter. State of New Jersey Common Pension Fund D raised its holdings in shares of Cytokinetics by 50.6% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 61,783 shares of the biopharmaceutical company’s stock valued at $2,041,000 after buying an additional 20,751 shares during the period. Finally, United Services Automobile Association acquired a new position in Cytokinetics during the 1st quarter worth approximately $331,000.

Insider Transactions at Cytokinetics

In related news, Director Wendell Wierenga sold 4,375 shares of the stock in a transaction that occurred on Monday, October 27th. The shares were sold at an average price of $58.68, for a total transaction of $256,725.00. Following the completion of the sale, the director owned 32,444 shares of the company’s stock, valued at approximately $1,903,813.92. This represents a 11.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Robert I. Blum sold 5,000 shares of Cytokinetics stock in a transaction that occurred on Thursday, October 30th. The shares were sold at an average price of $62.86, for a total transaction of $314,300.00. Following the transaction, the chief executive officer directly owned 358,108 shares in the company, valued at approximately $22,510,668.88. This trade represents a 1.38% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 56,983 shares of company stock valued at $3,165,356. Insiders own 2.70% of the company’s stock.

Cytokinetics Company Profile

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.